You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule treatments; Roche's Esbriet and Boehringer Ingelheim's Ofev. A number of growth drivers have emerged within the IPF market over the last five years, namely the acknowledgement of the lucrative IPF therapeutic market by pharmaceutical companies looking to meet the series of clinical unmet needs. These include both larger and smaller biotechnology companies alike. As such, the landscape will continue to evolve and the increasing uptake of current therapies and approval of new products will be the primary drivers of growth over the forecast period. Companies Mentioned Key Questions Answered Reasons to Buy Key Topics Covered: 1 Table of Contents 2 Idiopathic Pulmonary Fibrosis: Executive Summary 3 Introduction 4 Disease Overview 4.1 Etiology and Pathophysiology 4.1.1 Etiology 4.1.2 Pathophysiology 4.2 Classification or Staging Systems 4.2.1 GAP Model 4.2.2 Stratification by Decline in Forced Vital Capacity (FVC) 5 Epidemiology 5.1 Disease Background 5.2 Risk Factors and Comorbidities 5.3 Global and Historical Trends 5.4 Forecast Methodology 5.4.1 Sources Used 5.4.2 Forecast Assumptions and Methods 5.5 Epidemiological Forecast for IPF (2019-2029) 5.5.1 Diagnosed Incident Cases of IPF 5.5.2 Sex-Specific Diagnosed Incident Cases of IPF 5.5.3 Age-Specific Diagnosed Incident Cases of IPF 5.5.4 Diagnosed Prevalent Cases of IPF 5.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF 5.5.6 Age-Specific Diagnosed Prevalent Cases of IPF 5.5.7 Diagnosed Prevalent Cases of IPF by Severity 5.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities 5.5.9 Total Prevalent Cases of IPF 5.6 Discussion 6 Current Treatment Options 6.1 Overview 6.2 Current Treatment Guidelines 6.3 Symptomatic Treatments 7 Unmet Needs and Opportunity Assessment 7.1 Overview 7.2 Earlier Diagnosis 7.3 Improved Drug Safety and Efficacy 7.4 Improvement in Patient Quality of Life 7.5 Treatments for Patients with Severe Disease 8 R&D Strategies 8.1 Overview 8.1.1 Corporate Partnerships 8.1.2 Combination Therapy 8.2 Clinical Trial Design 8.2.1 Appropriate Endpoints 8.2.2 Increased Use of Quality of Life Measures 8.2.3 Add-Ons to Standard of Care 8.2.4 Selection of Patient Population 9 Impact of COVID-19 on the IPF Disease Space 9.1 Overview 9.2 Continuity of Care 9.3 Trial Logistics 9.3.1 Recruitment 9.3.2 Trial Conduct in Isolation 9.3.3 Supply Chain 9.4 Long-Term Impact on the Disease Space 10 Pipeline Assessment 10.1 Overview 10.2 Innovative Early-Stage Approaches 11 Pipeline Valuation Analysis 11.1 Clinical Benchmark of Key Pipeline Drugs 11.2 Commercial Benchmark of Key Pipeline Drugs 11.3 Competitive Assessment 11.4 Top-Line 10-Year Forecast 11.4.1 US 11.4.2 5EU 11.4.3 Japan 12 Appendix For more information about this report visit https://www.researchandmarkets.com/r/xxy8tx

Answer: 2020 Market Study on the Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 - ResearchAndMarkets.com